过去 90 天内没有内部人买入。最近一笔由 Heron Patrick J 披露于 2021年7月20日。
Imago BioSciences, Inc.：高管交易动态
本页追踪Imago BioSciences, Inc.高管申报的每一笔交易（来源：SEC (Form 4)）。公司属于医疗与制药行业。十二个月来，Imago BioSciences, Inc.的高管没有新的申报，最新记录停留在2023年1月11日。
我们关于Imago BioSciences, Inc.的记录可追溯至2021年，累计有5笔买入和34笔卖出。
数据来源：高管申报（SEC (Form 4)）。过往交易不代表未来收益。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位；其他市场的信号仍处于观察状态。并非投资建议。
财务数据
财年 2021财年截至 2021年12月 · cache
- 141,094 股@ US$36.0097.7% 占其流量股票SEC:0000899243-23-001606:0
- 246,453 股@ US$36.0098.3% 占其流量股票SEC:0000899243-23-001601:0
- 150,188 股@ US$36.0097.1% 占其流量股票SEC:0000899243-23-001589:0
- 26,538 股@ US$36.0091.8% 占其流量股票SEC:0000899243-23-001590:0
- 850 股@ US$36.0071.2% 占其流量股票SEC:0000899243-23-001585:0
- 51,532 股@ US$36.0035.8% 占其流量股票SEC:0000899243-23-001598:0
- 501,702 股@ US$36.0099.3% 占其流量股票SEC:0000899243-23-001602:0
- 26,095 股@ US$36.00100.0% 占其流量股票SEC:0000899243-23-001599:0
- 12,400 股@ US$4.200.5% 占其流量股票SEC:0001567619-23-000459:1
- 1,379 股@ US$22.760.3% 占其流量股票SEC:0001567619-23-000459:2
- 12,400 股@ US$4.200.4% 占其流量股票SEC:0001567619-23-000460:1
- 1,769 股@ US$22.760.3% 占其流量股票SEC:0001567619-23-000460:2
- 7,415 股@ US$2.520.1% 占其流量股票SEC:0001567619-23-000457:1
- 1,379 股@ US$22.760.6% 占其流量股票SEC:0001567619-23-000462:0
- 4,761 股@ US$2.520.1% 占其流量股票SEC:0001567619-23-000457:0
- 2,145 股@ US$15.450.6% 占其流量股票SEC:0001567619-23-000464:0
- 22,950 股@ US$2.520.6% 占其流量股票SEC:0001567619-23-000460:0
- 19,941 股@ US$4.208.2% 占其流量股票SEC:0001567619-23-000466:0
- 7,482 股@ US$2.520.4% 占其流量股票SEC:0001567619-23-000459:0
- 3,100 股@ US$35.930.8% 占其流量股票SEC:0001567619-22-022097:1
- 66,794 股@ US$18.4413.8% 占其流量股票SEC:0001567619-22-022096:1
- 70,508 股@ US$35.9328.5% 占其流量股票SEC:0001567619-22-022096:2
- 28,206 股@ US$15.458.5% 占其流量股票SEC:0001567619-22-022096:0
- 3,100 股@ US$2.520.1% 占其流量股票SEC:0001567619-22-022097:0
- 5,952 股@ US$2.190.1% 占其流量股票SEC:0001567619-22-021865:1
125 条申报中的 25 条
About Imago BioSciences, Inc.
Imago BioSciences, Inc. (ticker: IMGO) was a U.S.-listed biotechnology company that traded on the NASDAQ in the United States before being acquired by Merck in January 2023. Headquartered in South San Francisco, California, Imago was incorporated in 2012 and built its business around discovering and developing novel small-molecule therapies for blood cancers and other bone-marrow diseases. Its scientific focus was centered on lysine-specific demethylase 1 (LSD1), an epigenetic enzyme involved in blood-cell production in the bone marrow. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1623715/000156761922007538/0001567619-22-007538-index.htm?utm_source=openai))
The company’s lead asset was bomedemstat, an orally available LSD1 inhibitor. Imago developed this candidate primarily for myeloproliferative neoplasms (MPNs), a family of chronic bone-marrow cancers that includes essential thrombocythemia, myelofibrosis, and polycythemia vera. Imago positioned bomedemstat as a potentially disease-modifying therapy rather than a purely symptomatic treatment, and its development program included Phase 2 clinical studies as well as investigator-sponsored combination trials in hematologic and oncology settings. ([merck.com](https://www.merck.com/news/merck-to-acquire-imago-biosciences-inc/?utm_source=openai))
展开全文收起
From a market-positioning perspective, Imago was a niche clinical-stage biotech company operating in a highly competitive segment of the broader oncology and hematology landscape. Its differentiation came from the novelty of its biology, the focus on underserved marrow diseases, and the potential clinical utility of a first-in-class epigenetic approach. At the same time, the company had no commercial product revenue and therefore depended on clinical progress, regulatory execution, and capital access—classic risk factors for development-stage biotechnology investors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1623715/000119312521217482/d143204d424b4.htm?utm_source=openai))
A major recent milestone was Merck’s acquisition of Imago, announced in late 2022 and completed in January 2023, for about $1.35 billion in cash, or $36.00 per share. After closing, Imago ceased to exist as an independent public equity story; its former ticker IMGO became relevant mainly in the context of historical SEC filings, including Form 4 insider transaction records from the pre-acquisition period. For investors, the company is therefore best understood as a formerly listed U.S. NASDAQ biotech that was absorbed into a large-cap pharmaceutical platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/64978/000119312523006130/d377686dex99a5b.htm?utm_source=openai))
